Committed to support its partners from development up to finished product manufacturing, the new initiative enables industrial customers to have their freeze-dried bacteria produced to the highest quality standards such as ISO 9001, FAMI-QS, HACCP and ICHQ7A; up to GMP pharma for finished product compliance.
It also offers access to the company’s patented technology platforms for the protection of live bacteria for specific applications called STAR enterocoating technology and Probiocap microencapsulation technology.
The services operates three bacteria production facilities located in France (Aurillac), Canada (Montreal) and in the US (Milwaukee).